

# UCSF

## UC San Francisco Previously Published Works

### Title

The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantat...

### Permalink

<https://escholarship.org/uc/item/6p15z3dj>

### Journal

Transplantation and Cellular Therapy, 23(1)

### ISSN

2666-6375

### Authors

Dietz, Andrew C  
Duncan, Christine N  
Alter, Blanche P  
[et al.](#)

### Publication Date

2017

### DOI

10.1016/j.bbmt.2016.10.004

Peer reviewed



Published in final edited form as:

*Biol Blood Marrow Transplant*. 2017 January ; 23(1): 24–29. doi:10.1016/j.bbmt.2016.10.004.

## The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation (HCT): Defining the Unique Late Effects of Children undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies

Andrew C. Dietz<sup>1,\*</sup>, Christine N. Duncan<sup>2,\*</sup>, Blanche P. Alter<sup>3</sup>, Dorine Bresters<sup>4</sup>, Morton J. Cowan<sup>5</sup>, Luigi Notarangelo<sup>6</sup>, Philip S. Rosenberg<sup>7</sup>, Shalini Shenoy<sup>8</sup>, Roderick Skinner<sup>9</sup>, Mark C. Walters<sup>10</sup>, John Wagner<sup>11</sup>, K. Scott Baker<sup>12</sup>, and Michael A. Pulsipher<sup>1,\*\*</sup>

<sup>1</sup>Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, United States of America <sup>2</sup>Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States of America <sup>3</sup>Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America <sup>4</sup>Willem-Alexander Children's Hospital, SCT unit, Leiden University Medical Center, Leiden, The Netherlands <sup>5</sup>UCSF Department of Pediatrics, Allergy, Immunology, and Blood and Marrow Transplant Division, San Francisco California, United States of America <sup>6</sup>Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America <sup>7</sup>Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America <sup>8</sup>Washington University, St. Louis Children's Hospital, St. Louis, Missouri, United States of America <sup>9</sup>Great North Children's Hospital and Northern Institute of Cancer Research, Newcastle upon Tyne, United Kingdom <sup>10</sup>UCSF Benioff Children's Hospital Oakland, Oakland, California, United States of America <sup>11</sup>Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, United States of America <sup>12</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

### Abstract

An international consensus conference sponsored by the Pediatric Blood and Marrow Transplant consortium entitled, "Late Effects Screening and Recommendations Following Allogeneic

\*\*Corresponding Author: Michael A. Pulsipher, MD, Professor of Pediatrics, USC Keck School of Medicine, Section Head, Blood and Marrow Transplantation, Endowed Chair in Blood and Marrow Transplantation Clinical Research, Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, 4650 Sunset Blvd., Mailstop #54, Los Angeles, CA 90027, Ph: 323.361.8840 Fax: 323.361.8068, mpulsipher@chla.usc.edu.

\*Dr. Dietz and Dr. Duncan contributed equally.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Hematopoietic Cell Transplant for Immune Deficiency and Non-malignant Hematologic Disease was held in Minneapolis, Minnesota on May 10–11, 2016. The purpose of the conference was to address the unmet need for a greater understanding of and the screening for long-term complications in the growing population of survivors of transplantation for nonmalignant disorders. The conference focused on transplantation for hemoglobinopathy, immune deficiency, and inherited bone marrow syndromes. A multidisciplinary group of experts in the disease areas and transplant late effects presented the current state of understanding of how the underlying disease, pretransplant therapies, and transplant related factors uniquely interact to influence the development of late toxicities. Recommendations were put forth by the group for the late effects screening of survivors of transplantation for these non-malignant disorders. The findings and recommendations that came from this conference will be presented in a series of six additional manuscripts in the upcoming months. In this manuscript we explore the need for screening practices specific to the survivors of transplantation for non-malignant diseases and the methodologic challenges associated with the study of these patients.

### Keywords

Late effects; pediatric allogeneic bone marrow transplant; marrow failure disorders; immune deficiencies; hemoglobinopathies

### Background

Improvement in survival and a growing list of indications has led to an expanding population of survivors of allogeneic hematopoietic cell transplantation (HCT) in childhood.<sup>1–3</sup> A report from the Center for International Blood and Marrow Transplant Research (CIBMTR) estimates that there will be 242,000 survivors of transplantation by 2020 and 502,000 by 2030 representing a 2.5-fold and 5-fold increase from 2009 respectively.<sup>1</sup> It is predicted that in 2030, 14% of survivors will have been less than 18 years of age at transplantation.

In more recent years there has been a steady increase in the number of children transplanted for non-malignant diseases.<sup>4</sup> Between 2009 and 2013 there were 3151 HCTs performed in pediatric patients with immune system disorders, histiocytic diseases, inherited abnormalities of erythrocyte differentiation or function, inherited disorders of metabolism, inherited platelet abnormalities, inherited bone marrow failure syndromes and aplastic anemia.<sup>5</sup> Non-malignant conditions comprised 26.5% of the 11,875 transplants performed in patients less than 20 years of age representing a growing population of pediatric transplant survivors.<sup>5</sup>

Transplantation during childhood years can predispose children to late toxicities and consequently, increased morbidity and mortality compared with age and sex matched counterparts. Survivors of pediatric HCT for hematological malignancies have a much higher burden, both in terms of number and severity, of late effects as compared to childhood cancer survivors treated with chemotherapy only. The cumulative incidence of chronic health conditions after HCT with a median follow-up of 5 to 15 years varies from 30–60% with increasing risk over time.<sup>6–8</sup> Risk factors for late effects in HCT survivors include younger age at HCT, the use of total body irradiation (TBI) and chronic graft versus

host disease (GVHD).<sup>7-15</sup> Additionally, the Bone Marrow Transplant Survivor Study found an almost 10-fold increased risk of non-relapse late mortality after HCT compared with the general population, related to chronic GVHD, new malignancies, cardio-pulmonary late effects and other chronic health conditions.<sup>16</sup>

Despite the increasing numbers of survivors of HCT for non-malignant disorders, our knowledge of late effects following childhood transplantation comes primarily from the study of HCT for acute leukemia. With improving survival of childhood cancer patients, focus has shifted from improving survival to improving survival with the best quality of life. This has led to a wealth of studies on chronic health conditions in childhood cancer survivors and on treatment modalities that increase the risk for specific late effects, e.g. radiotherapy and secondary malignancy. However, fewer reports detail long-term follow-up after HCT for non-malignant diseases, in part due to the rarity of these conditions and the relatively recent evolution of HCT as a standard treatment option in disorders such as thalassemia and sickle cell disease, where the risk of dying in childhood from these disorders is very low and effective supportive care are in place. One recent single-institution study described late effects in 102 patients surviving for a minimum of 5 years after cord blood HCT. Busulfan was the primary conditioning agent and no TBI was given. HCT was for non-malignant indications in 82.4% of patients. Significant late effects identified included dental problems, short stature, cognitive deficits, pulmonary dysfunction, and abnormal pubertal development. At least 1 late effect was present in 98% of all patients.<sup>17</sup>

Non-malignant disorders treated by HCT including inherited bone marrow failure syndromes (IBMFS), hemoglobinopathies, and immune deficiencies adversely affect target organ function, cause cognitive impairment, and shorten survival. Single center and a smaller number of consortia reports have shown that long-term complications are common in survivors of transplantation for IBMFS, hemoglobinopathies and immune deficiencies, including infertility, endocrine issues, immunologic function, and sequelae of chronic GVHD.<sup>18-26</sup> The pre-transplant therapies and potential comorbidities of children with these disorders are unique and not readily interchangeable with comparisons with malignant diseases, which typically require chemotherapy treatment to induce remission prior to transplant. Therefore, knowledge gained from the study of late effects in leukemia does not necessarily apply to patients transplanted for non-malignant disorders. Efforts aimed at identifying how features of non-malignant disorders interact with the HCT process to increase the risk of long-term effects are vital in planning strategies to screen, diagnose and treat, or prevent these complications.

## Existing Consensus Guidelines

In 2011 the Pediatric Blood and Marrow Transplant Consortium (PBMTC), National Cancer Institute (NCI), and National Heart, Lung and Blood Institute (NHLBI) convened the First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation in Bethesda, Maryland. One of the seven manuscripts resulting from the conference highlighted the need for pediatric specific post-transplant late effects screening guidelines.<sup>27</sup> In that manuscript and others from the conference, the authors presented expert panel recommendations to screen for late effects following HCT in children.<sup>27-29</sup> In

Author Manuscript  
Author Manuscript  
Author Manuscript

addition, they provided critical review of the existing recommendations and applicability to survivors of childhood HCT. These recommendations came from multiple consortia including the Children's Oncology Group (COG), CIBMTR/American Society for Blood and Marrow Transplantation/Asia-Pacific Blood and Marrow Transplantation Group/Bone Marrow Transplant Society of Australia and New Zealand/East Mediterranean Blood and Marrow Transplantation Group/Sociedad Brasileira de Transplante de Medula Ossea, UK Children's Cancer and Leukaemia Group Late-Effects Group Therapy-Based Long-Term Follow-Up Practice Statement and PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies.<sup>27</sup> The guidelines from these groups differ in content, organization and emphasis placed on survivors of pediatric HCT. Table 1 outlines the recommendations for screening of organ systems that are most applicable in survivors after HCT for non-malignant diseases. A common weakness of the pediatric specific recommendations was the lack of focus on organ function and late complications that are specific to non-malignant disorders, a consequence of the fact that these guidelines have inevitably focused much more on malignant transplants due to greater numbers and more knowledge.

There are few consensus recommendations for late effects screening that take into account the features unique to non-malignant disorders. An exception is the most recent COG HCT specific surveillance recommendations.<sup>30</sup> The COG provides evidence-based, pediatric-specific recommendations organized by therapeutic exposure ([http://www.survivorshipguidelines.org/pdf/LTFUGuidelines\\_40.pdf](http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf)) with a separate section focused on post-HCT follow-up. These recommendations are presented in an organ system based approach.<sup>30</sup> Of note, the pre-transplant exposures considered in the COG recommendations focus on chemotherapy and radiation. They do not address common pre-transplant exposures in non-malignant patients such as hydroxyurea in patients with sickle cell anemia, chronic red blood cell transfusion and chelation agents in IBMFS and hemoglobinopathies, previous infections in immune deficiency patients, and androgen therapy in patients with IBMFS syndromes. We know of no consensus long-term screening guidelines that address the pathophysiology of the non-malignant conditions or the pre-transplantation therapies given to these patients. Also important is the need to account for individual disease related manifestations in the development of these screening guidelines.

In order to address the unique and critical needs of children undergoing HCT for non-malignant disorders, we convened a Second International PBMT Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation in Minneapolis in May, 2016. In a series of 6 manuscripts from this conference we will provide recommendations for long-term follow-up and late effects screening of survivors of HCT for severe immune deficiencies, specific marrow failure syndromes (Fanconi Anemia, Diamond-Blackfann Anemia, and Dyskeratosis Congenita) and common hemoglobinopathies (sickle cell disease and thalassemia). In addition, we will outline current knowledge of late effects in each disease and then specify scientific priorities for future late effects research. The greatest challenges in performing HCT in these patients are problems inherent in the underlying disease process, with a natural history of progression that may or may not be cured and in some cases can be potentially exacerbated by HCT. The recommendations will be unique to each of the three groups discussed at the conference: IBMFS, hemoglobinopathies, and

immune deficiencies. Our recommendations will outline an ideal for follow-up along with guidelines for critical minimal follow-up in order to be useful for populations with variable resources.

## Methodological Challenges

When considering how best to further study the ways in which HCT may interact with underlying disease, there are a number of methodological challenges.

The first challenge is to define the appropriate cohorts of patients with these rare conditions to address specific study questions and to ensure long-term access to them for follow-up studies. This applies to each of the retrospective, cross-sectional, and prospective studies needed to build a more comprehensive understanding of late effects after HCT in children with these disorders. With increasing success of HCT in non-malignant conditions, there are new cohorts surviving and teaching us more each day, while at the same time, there is often a long latency for many of the long-term conditions of interest. Advances will be strengthened if investigators develop consortia and combine databases that link multiple pediatric and adult institutions in global collaborations. Within these structures, there will need to be development of standardized data collection tools that can be complete and current, but will also account for time trends with long length of follow-up. Current infrastructure to address some of these questions resides within the CIBMTR and the Pediatric Diseases Working Party of the EBMT, but due the rare nature of these diseases and the complexity of the disorders, disease specific infrastructures are attempting to address these questions as well (i.e. the Primary Immune Deficiency Treatment Consortium, disease specific registries [Diamond-Blackfan Anemia and Schachmann-Diamond Registries], etc.).

Another major challenge in the study of late effects in non-malignant conditions lies in establishing an appropriate comparison group(s). Should patients with non-malignant disorders who undergo HCT be compared with patients with the same condition who do not undergo HCT, patients with other non-malignant disease conditions who also undergo HCT, or to patients who undergo HCT for malignant conditions? Comparisons with the general population are potentially problematic since the underlying disease may have other characteristics that lead to chronic health conditions unrelated to the HCT process. Examples of different comparisons include work done with Fanconi Anemia (FA) patients where those with and without HCT have been compared<sup>31</sup> and FA patients have been compared with other IBMFS patients as well as with population norms through the Surveillance, Epidemiology, and End Results (SEER) Program.<sup>32</sup> However, those patients transplanted are inherently different given that HCT is typically only offered to IBMFS patients who have had malignant transformation or who have severe bone marrow failure. Similar issues exist for patients with sickle cell anemia, who are eligible for HCT if they have a more severe phenotype with sickle related complications. There is a challenge to clarify if chronic health conditions and late effects are caused by the underlying disease, the HCT procedure and related complications, and/or the interaction of these. Choosing the right comparison groups can help to disentangle these elements and better define risk factors for HCT-specific late effects in these patients.

If appropriate cohort and comparators can be established, there are still challenging statistical questions that can arise. For example, time is an important factor, but time can be expressed as an interval after diagnosis, interval after intervention such as HCT, or attained age. Each study design will need to determine the most appropriate time scale for analyses. Additionally, it is important to define the analysis methods that will minimize bias. Competing risks, where patients may experience an event that changes risk of another event, will be best in some settings. In other settings actuarial analysis will be best, where a patient is censored at an event and those censored are representative of those who remain on study and would experience the event if followed long enough.

Ultimately, a critical aspect of these studies is to provide data allowing for shared decision-making, where clinicians can advise families on potential risks and benefits of transplant. An example of this kind of thought process is earlier or pre-emptive HCT in FA.<sup>33, 34</sup> The authors of these studies suggest the methods applied could be used to model survival for other disorders with limited empirical data and a pressing need for clinical guidelines.

## State of the Science and Future Directions

The International Consensus Conference in Minneapolis brought together international experts in hematology, immunology, blood and marrow transplantation, and survivorship from North America, South America, and Europe. The first half-day session focused on IBMFS, specifically FA, Dyskeratosis Congenita, and Diamond Blackfan Anemia. The second half-day session focused on hemoglobinopathies, specifically thalassemia and sickle-cell anemia. The third half-day session focused on primary immune deficiency with an emphasis on severe combined immunodeficiency. The current manuscript provides basic general recommendations for long-term follow-up from which more individualized recommendations can be created. Based on an exhaustive literature review, a series of pre-meeting conference calls, and summary discussions at the conference, each of the three working committees have prepared a two manuscripts—the first discussing knowledge to date and identified gaps, and the second outlining disease specific long-term follow-up recommendations. These publications will appear sequentially in BBMT for the next several months. It is our hope that this work will inspire and promote research in this area and for funding agencies to consider the importance of the priority studies outlined. We also hope to establish the key importance of specialized long-term follow-up and enjoin insurers to provide coverage for appropriate screening visits in these high risk children as they progress through their lives.

## Acknowledgments

Financial disclosure: This work was supported in part by grants from the National Institutes of Health (1R13CA159788-01 [to M.P., K.S.B.], U01HL069254 [to M.P.], R01 CA078938 [to S.B.], U54AI082973 [to M.J.C. and L.N.], R13AI094943 [M.J.C. and L.N.] and the St. Baldrick's Foundation [to M.P.]). B.P.A. and P.S.R are supported by the Intramural Research Program of the National Cancer Institute of the National Institutes of Health. R.S. is supported in part by the 7th Framework Programme of the EU, PanCareSurfUp (257505). The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding.

## References

1. Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL, et al. Prevalence of hematopoietic cell transplant survivors in the United States. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2013; 19(10):1498–1501. DOI: 10.1016/j.bbmt.2013.07.020
2. Svenberg P, Remberger M, Uzunel M, Mattsson J, Gustafsson B, Fjaertoft G, et al. Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation – A comparison of the last two decades. *Pediatric transplantation*. 2016; 20(5):667–674. DOI: 10.1111/ptr.12723 [PubMed: 27251184]
3. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorrow ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. *The New England journal of medicine*. 2010; 363(22):2091–2101. DOI: 10.1056/NEJMoa1004383 [PubMed: 21105791]
4. Ballen KK, King RJ, Chitphakdithai P, Bolan CD Jr, Agura E, Hartzman RJ, et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2008; 14(9 Suppl):2–7. DOI: 10.1016/j.bbmt.2008.05.017
5. Center for International Blood and Marrow Transplant acftCWBYCTPottUSDoHaHS. Number of HCTs performed in the United States and reported to CIBMTR by disease category and age by year. Last updated May 18, 2015. 2015
6. Schultz KA, Chen L, Chen Z, Kawashima T, Oeffinger KC, Woods WG, et al. Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children’s oncology group. *Pediatric blood & cancer*. 2014; 61(4):729–736. DOI: 10.1002/pbc.24881 [PubMed: 24285698]
7. Armenian SH, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). *Blood*. 2011; 118(5):1413–1420. DOI: 10.1182/blood-2011-01-331835 [PubMed: 21652685]
8. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. *Blood*. 2010; 116(17):3129–3139. quiz 3377. DOI: 10.1182/blood-2009-06-229369 [PubMed: 20656930]
9. Sun CL, Kersey JH, Francisco L, Armenian SH, Baker KS, Weisdorf DJ, et al. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study. *Biol Blood Marrow Transplant*. 2013; 19(7):1073–1080. DOI: 10.1016/j.bbmt.2013.04.002 [PubMed: 23583827]
10. Baker KS, Bresters D, Sande JE. The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children. *Pediatr Clin North Am*. 2010; 57(1): 323–342. DOI: 10.1016/j.pcl.2009.11.008 [PubMed: 20307723]
11. Bresters D, van Gils IC, Kollen WJ, Ball LM, Oostdijk W, van der Bom JG, et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. *Bone Marrow Transplant*. 2010; 45(1):79–85. DOI: 10.1038/bmt.2009.92 [PubMed: 19421172]
12. Ferry C, Gemayel G, Rocha V, Labopin M, Esperou H, Robin M, et al. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. *Bone Marrow Transplant*. 2007; 40(3):219–224. DOI: 10.1038/sj.bmt.1705710 [PubMed: 17530002]
13. Faraci M, Barra S, Cohen A, Lanino E, Grisolia F, Miano M, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. *International journal of radiation oncology, biology, physics*. 2005; 63(5):1568–1575. DOI: 10.1016/j.ijrobp.2005.04.031
14. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med*. 2006; 355(15):1572–1582. DOI: 10.1056/NEJMsa060185 [PubMed: 17035650]
15. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. *JAMA*. 2007; 297(24):2705–2715. DOI: 10.1001/jama.297.24.2705 [PubMed: 17595271]



16. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. *Blood*. 2007; 110(10):3784–3792. DOI: 10.1182/blood-2007-03-082933 [PubMed: 17671231]
17. Allewelt H, El-Khorazaty J, Mendizabal A, Taskindoust M, Martin PL, Prasad V, et al. Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2016; 22(9):1627–1635. DOI: 10.1016/j.bbmt.2016.05.024
18. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. *Blood*. 2007; 110(7):2749–2756. DOI: 10.1182/blood-2007-03-079665 [PubMed: 17606762]
19. Khalil A, Zaidman I, Elhasid R, Peretz-Nahum M, Futerman B, Ben-Arush M. Factors influencing outcome and incidence of late complications in children who underwent allogeneic hematopoietic stem cell transplantation for hemoglobinopathy. *Pediatric hematology and oncology*. 2012; 29(8):694–703. DOI: 10.3109/08880018.2012.725198 [PubMed: 23020512]
20. Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, et al. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. 2012; 18(12):1776–1784. e-pub ahead of print 2012/08/07. DOI: 10.1016/j.bbmt.2012.06.018 [PubMed: 22863842]
21. Sanders JE, Woolfrey AE, Carpenter PA, Storer BE, Hoffmeister PA, Deeg HJ, et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. *Blood*. 2011; 118(5):1421–1428. e-pub ahead of print 2011/06/10. DOI: 10.1182/blood-2011-02-334953 [PubMed: 21653322]
22. Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. *Blood*. 2015; 125(13):2164–2172. DOI: 10.1182/blood-2014-11-608075 [PubMed: 25624320]
23. Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for primary immunodeficiency disease. *Bone Marrow Transplant*. 2008; 41(2):119–126. DOI: 10.1038/sj.bmt.1705890 [PubMed: 17968328]
24. Horn B, Cowan MJ. Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects. *J Allergy Clin Immunol*. 2013; 131(5):1306–1311. DOI: 10.1016/j.jaci.2013.03.014 [PubMed: 23622119]
25. Anur P, Friedman DN, Sklar C, Oeffinger K, Castiel M, Kearney J, et al. Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors. *Bone Marrow Transplant*. 2016; 51(7):938–944. DOI: 10.1038/bmt.2016.32 [PubMed: 26999465]
26. Bonfim C, Ribeiro L, Nichele S, Bitencourt M, Loth G, Koliski A, et al. Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. *Biol Blood Marrow Transplant*. 2016; 22(7):1257–1263. DOI: 10.1016/j.bbmt.2016.03.007 [PubMed: 26976241]
27. Pulsipher MA, Skinner R, McDonald GB, Hingorani S, Armenian SH, Cooke KR, et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. *Biol Blood Marrow Transplant*. 2012; 18(3):334–347. e-pub ahead of print 2012/01/18. DOI: 10.1016/j.bbmt.2012.01.003 [PubMed: 22248713]
28. Nieder ML, McDonald GB, Kida A, Hingorani S, Armenian SH, Cooke KR, et al. National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2011; 17(11):1573–1584. DOI: 10.1016/j.bbmt.2011.09.013

29. Dvorak CC, Gracia CR, Sanders JE, Cheng EY, Baker KS, Pulsipher MA, et al. NCI, NHLBI/PBMTTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2011; 17(12):1725–1738. DOI: 10.1016/j.bbmt.2011.10.006
30. Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GM, Huang JT, et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children’s Oncology Group Report. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2016; 22(5):782–795. DOI: 10.1016/j.bbmt.2016.01.023
31. Rosenberg PS, Socié G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. *Blood*. 2005; 105(1):67–73. DOI: 10.1182/blood-2004-04-1652 [PubMed: 15331448]
32. Alter BP, Giri N, Savage SA, Peters JA, Loud JT, Leathwood L, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. *British journal of haematology*. 2010; 150(2):179–188. e-pub ahead of print 2010/05/29. DOI: 10.1111/j.1365-2141.2010.08212.x [PubMed: 20507306]
33. Khan NE, Rosenberg PS, Lehmann HP, Alter BP. Preemptive Bone Marrow Transplantation for FANCD1/BRCA2. *Biol Blood Marrow Transplant*. 2015; 21(10):1796–1801. DOI: 10.1016/j.bbmt.2015.07.006 [PubMed: 26183081]
34. Khan NE, Rosenberg PS, Alter BP. Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia. *Biol Blood Marrow Transplant*. 2016; 22(10):1888–1892. DOI: 10.1016/j.bbmt.2016.06.018 [PubMed: 27345141]
35. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2012; 18(3):348–371. DOI: 10.1016/j.bbmt.2011.12.519
36. Bunin N, Small T, Szabolcs P, Baker KS, Pulsipher MA, Torgerson T. NCI, NHLBI/PBMTTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2012; 18(1):6–15. DOI: 10.1016/j.bbmt.2011.11.014

Select current recommendations

	Children's Oncology Group	Combined HCT Consortia <sup>35</sup>	PBMTC Consensus Conference <sup>27, 36</sup>
<b>Late effect/Organ/System</b>			
<b>Immune reconstitution/Immunologic</b>	<ul style="list-style-type: none"> <li>Consideration for antibiotic prophylaxis against encapsulated organisms for the duration of immunosuppressive therapy and broad spectrum parenteral antibiotics for fevers &gt;101°F (38.3°C) in patients with active chronic GVHD</li> <li>Annual evaluation for chronic conjunctivitis, sinopulmonary infection, or recurrent, unusual, or severe infections in patients with chronic GVHD</li> <li>Screening for HIV and hepatitis C if exposed to blood products before universal screening</li> <li>Vaccinations according to national and professional society guidelines</li> </ul>	<ul style="list-style-type: none"> <li>Immunizations post-HCT according to published guidelines</li> <li>Administration of antibiotics for endocarditis prophylaxis according to AHA guidelines</li> <li>Patients with cGVHD:                             <ul style="list-style-type: none"> <li>Antimicrobial prophylaxis targeting encapsulated organisms and PCP for the duration of immunosuppressive therapy</li> <li>Screening for CMV reactivation should be based on risk factors</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Monitoring T cell reconstitution with lymphocyte subset analysis, high content immunophenotyping, and evaluation of T cell proliferative capacity to mitogens</li> <li>High content B cell immunophenotyping beginning 6 months after HCT</li> <li>Neoantigen challenge for patients with poor or incomplete immune reconstitution based on immunophenotyping</li> </ul>
<b>Iron overload</b>	<ul style="list-style-type: none"> <li>Assessment of serum ferritin one year after transplant with repeat testing or hepatology consult as clinically indicated; consider further evaluation of iron burden and treatment of any iron overload with phlebotomy or chelation therapy.</li> </ul>	<ul style="list-style-type: none"> <li>LFTs every 3–6 months in the first year, then individualized, but at least yearly thereafter</li> <li>Serum ferritin at 1 year after HCT in patients who received RBC transfusions; consider liver biopsy or imaging study for abnormal results based on magnitude of elevation and clinical context; subsequent monitoring is suggested for patients with elevated LFTs, continued RBC transfusions, or presence of HCV infections</li> </ul>	<ul style="list-style-type: none"> <li>Annual serum ferritin, consider T2* MRI if elevated</li> <li>Management: phlebotomy or chelation</li> </ul>
<b>Neurocognitive</b>	<ul style="list-style-type: none"> <li>Yearly screening for educational/vocational progress; formal neuropsychological evaluation at 1 year and periodically thereafter among survivors with concerns</li> <li>Referral to a school liaison or appropriately resourced medical center for survivors with neurocognitive deficits; consideration for psychotropic medication and/evidence-based rehabilitation training</li> </ul>	<ul style="list-style-type: none"> <li>Clinical evaluation for symptoms and signs of neurological dysfunction at 1 year and yearly thereafter; diagnostic testing for those with symptoms or signs</li> <li>Annual assessment for cognitive developmental milestones (pediatric specific recommendation)</li> </ul>	
<b>Subsequent cancer risk</b>	<ul style="list-style-type: none"> <li>All survivors should be counseled with regard to lifestyle factors that influence future cancer risk; general recommendation for annual history and physical exam and detailed recommendations for specific solid tumors provided</li> </ul>	<ul style="list-style-type: none"> <li>Counsel patients about risks of secondary malignancies annually and encourage them to perform self exam (e.g. skin, testicles/genitalia)</li> <li>Counsel patients to avoid high-risk behaviors</li> <li>Follow general population recommendations for cancer screening</li> <li>Patients with cGVHD; clinical and dental evaluation with particular attention toward oral and pharyngeal cancer</li> </ul>	No formal recommendations

	Children's Oncology Group	Combined HCT Consortia <sup>35</sup>	PBMTC Consensus Conference <sup>27, 36</sup>
<b>Pulmonary</b>	<ul style="list-style-type: none"> <li>Annual assessment for signs and symptoms of pulmonary dysfunction and PFT (1 year after HCT or when age appropriate, whichever is later) in patients who received bleomycin, busulfan, nitrosurea, and chest radiation or who have a history of chronic GVHD</li> <li>Counsel regarding tobacco avoidance/smoking cessation</li> </ul>	<ul style="list-style-type: none"> <li>TBI and chest irradiation recipients: screening mammography in women starting at age 25 or 8 years after radiation exposure, whichever occurs later (no later than 40 years)</li> <li>Clinical evaluation at 6 months and 1 year after HCT and at least yearly thereafter</li> <li>Assessment of tobacco use and counseling against smoking</li> <li>PFT and focused radiological assessment for allogeneic HCT recipients with symptoms or signs of lung compromise</li> </ul>	<ul style="list-style-type: none"> <li>PFT for allogeneic recipients twice per year for 2 years, with consideration for more frequent screening in recipients of mismatched or URD grafts, or patients with acute chronic GVHD; after 2 years, consider yearly follow-up PFT based on symptoms and past measurements</li> <li>With a 15% decrease in PFT values or new pulmonary infiltrate, evaluate for infection/GVHD. Refer to pulmonologist for disease-specific care as needed</li> </ul>
<b>Reproductive/Gonadal</b>	<ul style="list-style-type: none"> <li>Annual assessment of pubertal development, sexual and reproductive function in patients exposed to TBI, cranial radiation, alkylating or similar crosslinking agents</li> <li>Morning testosterone assessment beginning no later than 14 years and as clinically indicated in at risk males</li> <li>LH, FSH, and estradiol levels beginning no later than 13 years of age in at risk females</li> <li>Evaluation for vaginal fibrosis and stenosis in females who received radiation to the reproductive syndrome or chronic GVHD</li> <li>Referral to endocrinology, gynecology, or urology for patients with abnormal pubertal timing or gonadal dysfunction</li> </ul>	<ul style="list-style-type: none"> <li>Clinical and endocrinologic gonadal assessment for prepubertal boys and girls within 1 year of transplant, with further follow-up as determined in consultation with a pediatric endocrinologist (pediatric specific recommendation)</li> <li>Clinical and endocrinologic gonadal assessment for post-pubertal women at 1-year, subsequent follow-up based on menopausal status</li> <li>Gonadal function in men, including FSH, LH, and testosterone, should be assessed as warranted by symptoms</li> <li>Consider referral to appropriate specialists for patients who are contemplating a pregnancy or who are having difficulty conceiving</li> <li>Counsel sexually active patients in the reproductive age group about birth control</li> </ul>	<ul style="list-style-type: none"> <li>Women:                             <ul style="list-style-type: none"> <li>Monitor for ovarian failure (FSH, assess cycling)</li> <li>Anti-Mullerian hormone may assess ovarian reserve</li> <li>Treat ovarian failure with hormone replacement therapy</li> </ul> </li> <li>Men:                             <ul style="list-style-type: none"> <li>Semen analysis</li> <li>If oligospermia noted, may offer intracytoplasmic sperm injection</li> </ul> </li> </ul>
<b>Renal</b>	<ul style="list-style-type: none"> <li>Annual hypertension screening</li> <li>Annual urinalyses with measurement of BUN, creatinine, and electrolytes at 1 year after transplantation, and then as clinically indicated</li> </ul>	<ul style="list-style-type: none"> <li>Blood pressure assessment at every clinic visit, with aggressive hypertension management</li> <li>Assess renal function with BUN, creatinine, and urine protein at 6 months, 1 year, and at least yearly thereafter</li> <li>Consider further workup (kidney biopsy or renal ultrasound) of renal dysfunction as clinically indicated</li> </ul>	<ul style="list-style-type: none"> <li>Urine albumin: creatinine ratio at day 80, then annually; if ratio &gt;30 and &lt;300 mg/g, then confirm with 2 or more tests in 3–6 months and monitor every 3–6 months; if ratio is &gt;300 mg/g monitor every 3–6 months</li> <li>Treat with angiotensin converting enzyme inhibitor or angiotensin blocker if albumin: creatinine ratio is &gt;300 mg/g on one occasion or persistent ratio &gt; 30g/kg on 3 occasions in a 6 month period and hypertensive</li> </ul>
<b>Growth</b>	<ul style="list-style-type: none"> <li>Height, weight, BMI, and Tanner staging every 6 months until skeletal maturity reached</li> <li>Thyroid function, bone age evaluation and referral to endocrinology if the growth rate is abnormal</li> </ul>	<ul style="list-style-type: none"> <li>Monitor growth velocity in children annually; assessment of thyroid, and growth hormone function if clinically indicated</li> </ul>	<ul style="list-style-type: none"> <li>Accurate measurement of growth yearly through full growth</li> <li>Bone age as needed</li> </ul>

	Children's Oncology Group	Combined HCT Consortia <sup>35</sup>	PBMTC Consensus Conference <sup>27, 36</sup>
<b>Psychosocial</b>	<ul style="list-style-type: none"> <li>Referral to endocrinology if received &gt;/30 Gy of cranial radiation</li> <li>Annual psychosocial assessment with attention to social withdrawal, educational/vocational progress, chronic fatigue, pain, risk behaviors, and mental health concerns</li> <li>All survivors should be asked about their access to insurance and health care</li> </ul>	<ul style="list-style-type: none"> <li>Clinical assessment throughout recovery period, at 6 months, 1 year and annually thereafter, with mental health professional counseling recommended for those with recognized deficits</li> <li>Encouragement of robust support networks</li> <li>Regularly assess level of spousal/caregiver psychological adjustment and family functioning</li> </ul>	<ul style="list-style-type: none"> <li>Bone age and referral to an endocrine specialist for a patient not growing appropriately</li> </ul> <p>No formal recommendations</p>

\* Separate HCT section embedded in oncology surveillance guidelines. LFT = liver function tests; ALT = alanine transaminase; AST = aspartate transaminase; PFT = pulmonary function testing; AHA = American Heart Association